Francisco J. Vizoso

Dr. Francisco J. Vizoso

Fundacion Hospital de Jove
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FVFrancisco J. Vizoso
Francisco J. Vizoso
NENoemi Eiro
Noemi Eiro
FVFrancisco J. Vizoso
Francisco J. Vizoso
JSJ. Schneider
J. Schneider
RPRoman Perez-Fernandez
Roman Perez-Fernandez
Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to their capacity for local engrafting and differentiating into multiple tissue types. However, recent studies have revealed that implanted cells do not survive for long, and that the benefits of MSC therapy could be due to the vast array of bioactive factors they produce, which play an important role in the regulation of key biologic processes. Secretome derivatives, such as conditioned media or exosomes, may present considerable advantages over cells for manufacturing, storage, handling, product shelf life and their potential as a ready-to-go biologic product. Nevertheless, regulatory requirements for manufacturing and quality control will be necessary to establish the safety and efficacy profile of these products. Among MSCs, human uterine cervical stem cells (hUCESCs) may be a good candidate for obtaining secretome-derived products. hUCESCs are obtained by Pap cervical smear, which is a less invasive and painful method than those used for obtaining other MSCs (for example, from bone marrow or adipose tissue). Moreover, due to easy isolation and a high proliferative rate, it is possible to obtain large amounts of hUCESCs or secretome-derived products for research and clinical use.

22 July 2020 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
LCLuis A. Costa
Luis A. Costa
NENoemi Eiro
Noemi Eiro
MFMaría Fraile
María Fraile
LGLuis O. Gonzalez
Luis O. Gonzalez
JSJorge Saá
Jorge Saá
FVFrancisco J. Vizoso
Francisco J. Vizoso

3 December 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SGSalomé González-Reyes
Salomé González-Reyes
LMLaura Marín
Laura Marín
LLLucía González Llorente
Lucía González Llorente
LGLuis O González
Luis O González
JCJosé M del Casar
José M del Casar
FVFrancisco J. Vizoso
Francisco J. Vizoso
Background: Toll-like receptors (TLRs) have garnered an extraordinary amount of interest in cancer research due to their role in tumor progression. By activating the production of several biological factors, TLRs induce type I interferons and other cytokines, which drive an inflammatory response and activate the adaptive immune system. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4 and 9 in breast cancer. Methods: The expression levels of TLR3, TLR4 and TLR9 were analyzed on tumors from 74 patients with breast cancer. The analysis was performed by immunohistochemistry. Results: Samples of carcinomas with recurrence exhibited a significant increase in the mRNA levels of TLR3, TLR4 and TLR9. Tumors showed high expression of TLRs expression levels by cancer cells, especially TLR4 and 9. Nevertheless, a significant percentage of tumors also showed TLR4 expression by mononuclear inflammatory cells (21.6%) and TLR9 expression by fibroblast-like cells (57.5%). Tumors with high TLR3 expression by tumor cell or with high TLR4 expression by mononuclear inflammatory cells were significantly associated with higher probability of metastasis. However, tumours with high TLR9 expression by fibroblast-like cells were associated with low probability of metastasis. Conclusions: The expression levels of TLR3, TLR4 and TLR9 have clinical interest as indicators of tumor aggressiveness in breast cancer. TLRs may represent therapeutic targets in breast cancer.

27 October 2010 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
SGSalomé González-Reyes
Salomé González-Reyes
JFJesús M. Fernández
Jesús M. Fernández
LGLuis O. González
Luis O. González
AAAlina Aguirre
Alina Aguirre
ASAurelio Suárez
Aurelio Suárez
FVFrancisco J. Vizoso
Francisco J. Vizoso

3 October 2013 in Histopathology
Verified
Journal Article
Closed access
PDF file
BFBelen Fernandez‐Garcia
Belen Fernandez‐Garcia
NENoemi Eiro
Noemi Eiro
LMLaura Marín
Laura Marín
SGSalomé González‐Reyes
Salomé González‐Reyes
LGLuis O González
Luis O González
FVFrancisco J. Vizoso
Francisco J. Vizoso

1 January 2012 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
NENoemi Eiro
Noemi Eiro
FVFrancisco J. Vizoso
Francisco J. Vizoso
There is evidence supporting the hypothesis that inflammation participates in providing conditions that lead to cancer. An unresolved inflammation due to any failure in the precise control of the immune response can continue to perturb the cellular microenvironment, thereby leading to alterations in cancer-related genes and posttranslational modification in crucial cellular proteins involved in the cell cycle, DNA repair and apoptosis. In addition, there are data indicating that inflammatory cells and immunomodulatory mediators present in the tumor microenvironment influence tumor progression and metastasis. Historically, tumor-infiltrating leukocytes have been considered to be manifestations of an intrinsic defence mechanism against developing tumors. However, increasing evidence indicates that leukocyte infiltration can promote tumor phenotypes, such as angiogenesis, growth and invasion. This may be due to inflammatory cells that probably can influence cancer promotion by secreting cytokines, growth factors, chemokines and proteases, which stimulate proliferation and invasiveness of cancer cells. Consequently, events and molecules implicated in this cross talk between the tumor microenvironment and inflammatory process may emerge as attractive targets in anticancer therapeutic interventions with significant clinical impact.